{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:39:49Z","timestamp":1792571989434,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Plan Project of Jiangxi Provincial Health Commission","award":["SKJP1320242247"],"award-info":[{"award-number":["SKJP1320242247"]}],"id":[{"id":"https:\/\/ror.org\/03vc7fb96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05705-9","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:08:41Z","timestamp":1789463321000},"page":"5437-5454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer-associated fibroblasts drive immune resistance in MSS colorectal cancer via the FAIM2-CES1-ER stress pathway"],"prefix":"10.1007","volume":"481","author":[{"given":"Ren","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangpeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0729-074X","authenticated-orcid":false,"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-9646","authenticated-orcid":false,"given":"Jianyong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"5705_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081530","author":"G Roshandel","year":"2024","unstructured":"Roshandel G, Ghasemi-Kebria F, Malekzadeh R (2024) Colorectal cancer: epidemiology, risk factors, and prevention. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16081530","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5705_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338\u2013344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"issue":"4","key":"5705_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11912-023-01378-5","volume":"25","author":"A Damato","year":"2023","unstructured":"Damato A, Ghidini M, Dottorini L, Tomasello G, Iaculli A, Ghidini A et al (2023) Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. Curr Oncol Rep 25(4):341\u2013352. https:\/\/doi.org\/10.1007\/s11912-023-01378-5","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"5705_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"YH Xie","year":"2020","unstructured":"Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target therapy 5(1):22. https:\/\/doi.org\/10.1038\/s41392-020-0116-z","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"5705_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","volume":"10","author":"J Nors","year":"2024","unstructured":"Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL (2024) Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncol 10(1):54\u201362. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5098","journal-title":"JAMA Oncol"},{"issue":"10","key":"5705_CR6","doi-asserted-by":"publisher","first-page":"11073","DOI":"10.1002\/cam4.5594","volume":"12","author":"SC Ma","year":"2023","unstructured":"Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB et al (2023) Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med 12(10):11073\u201311096. https:\/\/doi.org\/10.1002\/cam4.5594","journal-title":"Cancer Med"},{"issue":"1","key":"5705_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23(1):64. https:\/\/doi.org\/10.1186\/s12935-023-02902-0","journal-title":"Cancer Cell Int"},{"issue":"Suppl 1","key":"5705_CR8","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y (2019) PD-1\/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 24(Suppl 1):S31\u2013s41. https:\/\/doi.org\/10.1634\/theoncologist.2019-IO-S1-s05","journal-title":"Oncologist"},{"key":"5705_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","volume":"175","author":"J Taieb","year":"2022","unstructured":"Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM (2022) Deficient mismatch repair\/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J cancer (Oxford England: 1990) 175:136\u2013157. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.020","journal-title":"Eur J cancer (Oxford England: 1990)"},{"key":"5705_CR10","doi-asserted-by":"publisher","first-page":"1019582","DOI":"10.3389\/fimmu.2022.1019582","volume":"13","author":"WJ Mei","year":"2022","unstructured":"Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR (2022) Clinicopathological characteristics of high microsatellite instability\/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol 13:1019582. https:\/\/doi.org\/10.3389\/fimmu.2022.1019582","journal-title":"Front Immunol"},{"issue":"14","key":"5705_CR11","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X et al (2021) Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 17(14):3837\u20133849. https:\/\/doi.org\/10.7150\/ijbs.64077","journal-title":"Int J Biol Sci"},{"issue":"2","key":"5705_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5306\/wjco.v14.i2.81","volume":"14","author":"SX Ma","year":"2023","unstructured":"Ma SX, Li L, Cai H, Guo TK, Zhang LS (2023) Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. World J Clin Oncol 14(2):81\u201388. https:\/\/doi.org\/10.5306\/wjco.v14.i2.81","journal-title":"World J Clin Oncol"},{"issue":"12","key":"5705_CR13","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","volume":"72","author":"KX Lin","year":"2023","unstructured":"Lin KX, Istl AC, Quan D, Skaro A, Tang E, Zheng X (2023) PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol immunotherapy: CII 72(12):3875\u20133893. https:\/\/doi.org\/10.1007\/s00262-023-03520-5","journal-title":"Cancer Immunol immunotherapy: CII"},{"key":"5705_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3332\/ecancer.2024.1771","volume":"18","author":"MPS Aruquipa","year":"2024","unstructured":"Aruquipa MPS, Donadio MS, Peixoto RD (2024) Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review. Ecancermedicalscience 18:1771. https:\/\/doi.org\/10.3332\/ecancer.2024.1771","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"5705_CR15","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1038\/s41467-023-39953-w","volume":"14","author":"E Koncina","year":"2023","unstructured":"Koncina E, Nurmik M, Pozdeev VI, Gilson C, Tsenkova M, Begaj R et al (2023) IL1R1(+) cancer-associated fibroblasts drive tumor development and immunosuppression in colorectal cancer. Nat Commun 14(1):4251. https:\/\/doi.org\/10.1038\/s41467-023-39953-w","journal-title":"Nat Commun"},{"issue":"3","key":"5705_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA (2023) Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell 41(3):434\u2013449. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.015","journal-title":"Cancer Cell"},{"issue":"9","key":"5705_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582\u2013598. https:\/\/doi.org\/10.1038\/nrc.2016.73","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5705_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA (2021) Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev 101(1):147\u2013176. https:\/\/doi.org\/10.1152\/physrev.00048.2019","journal-title":"Physiol Rev"},{"key":"5705_CR19","doi-asserted-by":"publisher","first-page":"1491400","DOI":"10.3389\/fphar.2024.1491400","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, Xu X, Li J, Xue Y, Li X, Zhang K et al (2024) Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies. Front Pharmacol 15:1491400. https:\/\/doi.org\/10.3389\/fphar.2024.1491400","journal-title":"Front Pharmacol"},{"issue":"2","key":"5705_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/neuonc\/noad173","volume":"26","author":"TL Zhang","year":"2024","unstructured":"Zhang TL, Xia C, Zheng BW, Hu HH, Jiang LX, Escobar D et al (2024) Integrating single-cell and spatial transcriptomics reveals endoplasmic reticulum stress-related CAF subpopulations associated with chordoma progression. Neurooncology 26(2):295\u2013308. https:\/\/doi.org\/10.1093\/neuonc\/noad173","journal-title":"Neurooncology"},{"key":"5705_CR21","doi-asserted-by":"publisher","first-page":"114762","DOI":"10.1016\/j.biopha.2023.114762","volume":"163","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhang X, Yang H, Liang T, Bai X (2023) The Self-eating of cancer-associated fibroblast: A potential target for cancer. Biomed pharmacotherapy = Biomedecine pharmacotherapie 163:114762. https:\/\/doi.org\/10.1016\/j.biopha.2023.114762","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"3","key":"5705_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/03008207.2022.2036735","volume":"63","author":"JF Bateman","year":"2022","unstructured":"Bateman JF, Shoulders MD, Lamand\u00e9 SR (2022) Collagen misfolding mutations: the contribution of the unfolded protein response to the molecular pathology. Connect Tissue Res 63(3):210\u2013227. https:\/\/doi.org\/10.1080\/03008207.2022.2036735","journal-title":"Connect Tissue Res"},{"key":"5705_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126520","author":"M Khoonkari","year":"2022","unstructured":"Khoonkari M, Liang D, Lima MT, van der Land T, Liang Y, Sun J et al (2022) The unfolded protein response sensor PERK mediates stiffness-dependent adaptation in glioblastoma cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23126520","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5705_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ et al (2021) Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol 14(1):98. https:\/\/doi.org\/10.1186\/s13045-021-01103-4","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5705_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z et al (2024) Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target therapy 9(1):225. https:\/\/doi.org\/10.1038\/s41392-024-01947-5","journal-title":"Signal Transduct Target therapy"},{"issue":"9","key":"5705_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC (2024) Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer 24(9):629\u2013646. https:\/\/doi.org\/10.1038\/s41568-024-00728-0","journal-title":"Nat Rev Cancer"},{"key":"5705_CR27","doi-asserted-by":"publisher","first-page":"1166497","DOI":"10.3389\/fimmu.2023.1166497","volume":"14","author":"T Shang","year":"2023","unstructured":"Shang T, Jiang T, Lu T, Wang H, Cui X, Pan Y et al (2023) Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Front Immunol 14:1166497. https:\/\/doi.org\/10.3389\/fimmu.2023.1166497","journal-title":"Front Immunol"},{"issue":"1","key":"5705_CR28","doi-asserted-by":"publisher","first-page":"2400314","DOI":"10.1080\/07853890.2024.2400314","volume":"56","author":"J Lv","year":"2024","unstructured":"Lv J, Zhang X, Zhou M, Yan J, Chao G, Zhang S (2024) Tertiary lymphoid structures in colorectal cancer. Ann Med 56(1):2400314. https:\/\/doi.org\/10.1080\/07853890.2024.2400314","journal-title":"Ann Med"},{"key":"5705_CR29","doi-asserted-by":"publisher","first-page":"1221532","DOI":"10.3389\/fimmu.2023.1221532","volume":"14","author":"RA O\u2019Connor","year":"2023","unstructured":"O\u2019Connor RA, Martinez BR, Koppensteiner L, Mathieson L, Akram AR (2023) Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta. Front Immunol 14:1221532. https:\/\/doi.org\/10.3389\/fimmu.2023.1221532","journal-title":"Front Immunol"},{"key":"5705_CR30","doi-asserted-by":"publisher","first-page":"105003","DOI":"10.1016\/j.ebiom.2024.105003","volume":"101","author":"F Di Modugno","year":"2024","unstructured":"Di Modugno F, Di Carlo A, Spada S, Palermo B, D\u2019Ambrosio L, D\u2019Andrea D et al (2024) Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. EBioMedicine 101:105003. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105003","journal-title":"EBioMedicine"},{"issue":"2","key":"5705_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s44321-023-00015-9","volume":"16","author":"Y Bai","year":"2024","unstructured":"Bai Y, Li T, Wang Q, You W, Yang H, Xu X et al (2024) Shaping immune landscape of colorectal cancer by cholesterol metabolites. EMBO Mol Med 16(2):334\u2013360. https:\/\/doi.org\/10.1038\/s44321-023-00015-9","journal-title":"EMBO Mol Med"},{"issue":"1","key":"5705_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A et al (2024) Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application. Mol Cancer 23(1):75. https:\/\/doi.org\/10.1186\/s12943-024-01980-6","journal-title":"Mol Cancer"},{"issue":"1","key":"5705_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1186\/s12885-022-09736-5","volume":"22","author":"C Ucaryilmaz Metin","year":"2022","unstructured":"Ucaryilmaz Metin C, Ozcan G (2022) Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. BMC Cancer 22(1):692. https:\/\/doi.org\/10.1186\/s12885-022-09736-5","journal-title":"BMC Cancer"},{"issue":"2","key":"5705_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13402-023-00888-5","volume":"47","author":"J Liu","year":"2024","unstructured":"Liu J, Ouyang Y, Xia Z, Mai W, Song H, Zhou F et al (2024) FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC. Cell Oncol (Dordrecht Netherlands) 47(2):623\u2013638. https:\/\/doi.org\/10.1007\/s13402-023-00888-5","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"issue":"1","key":"5705_CR35","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.yexcr.2022.113195","volume":"417","author":"BC Jena","year":"2022","unstructured":"Jena BC, Das CK, Banerjee I, Bharadwaj D, Majumder R, Das S et al (2022) TGF-\u03b21 induced autophagy in cancer associated fibroblasts during hypoxia contributes EMT and glycolysis via MCT4 upregulation. Exp Cell Res 417(1):113195. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113195","journal-title":"Exp Cell Res"},{"key":"5705_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814066","author":"S Shreya","year":"2023","unstructured":"Shreya S, Grosset CF, Jain BP (2023) Unfolded protein response signaling in liver disorders: a 2023 updated review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241814066","journal-title":"Int J Mol Sci"},{"key":"5705_CR37","doi-asserted-by":"publisher","first-page":"1440830","DOI":"10.3389\/fimmu.2024.1440830","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, Yu M, Zhang S (2024) The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies. Front Immunol 15:1440830. https:\/\/doi.org\/10.3389\/fimmu.2024.1440830","journal-title":"Front Immunol"},{"issue":"1","key":"5705_CR38","doi-asserted-by":"publisher","first-page":"e985940","DOI":"10.4161\/2162402x.2014.985940","volume":"4","author":"E Vacchelli","year":"2015","unstructured":"Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH et al (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 4(1):e985940. https:\/\/doi.org\/10.4161\/2162402x.2014.985940","journal-title":"Oncoimmunology"},{"key":"5705_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2020.10.040","volume":"498","author":"M Feng","year":"2021","unstructured":"Feng M, Zhao Z, Yang M, Ji J, Zhu D (2021) T-cell-based immunotherapy in colorectal cancer. Cancer Lett 498:201\u2013209. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.040","journal-title":"Cancer Lett"},{"key":"5705_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102718","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G et al (2023) Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15102718","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5705_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J et al (2024) Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol 17(1):65. https:\/\/doi.org\/10.1186\/s13045-024-01578-x","journal-title":"J Hematol Oncol"},{"issue":"5","key":"5705_CR42","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","volume":"29","author":"DC Guven","year":"2024","unstructured":"Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A et al (2024) The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review. Oncologist 29(5):e580\u2013e600. https:\/\/doi.org\/10.1093\/oncolo\/oyae013","journal-title":"Oncologist"},{"key":"5705_CR43","doi-asserted-by":"publisher","first-page":"108962","DOI":"10.1016\/j.clim.2022.108962","volume":"237","author":"L Chen","year":"2022","unstructured":"Chen L, Jiang X, Li Y, Zhang Q, Li Q, Zhang X et al (2022) How to overcome tumor resistance to anti-PD-1\/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clin Immunol 237:108962. https:\/\/doi.org\/10.1016\/j.clim.2022.108962","journal-title":"Clin Immunol"},{"issue":"6","key":"5705_CR44","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41556-022-00918-8","volume":"24","author":"II Verginadis","year":"2022","unstructured":"Verginadis II, Avgousti H, Monslow J, Skoufos G, Chinga F, Kim K et al (2022) A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat Cell Biol 24(6):940\u2013953. https:\/\/doi.org\/10.1038\/s41556-022-00918-8","journal-title":"Nat Cell Biol"},{"issue":"5","key":"5705_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1165\/rcmb.2023-0379OC","volume":"71","author":"JE Druso","year":"2024","unstructured":"Druso JE, MacPherson MB, Chia SB, Elko E, Aboushousha R, Seward DJ et al (2024) Endoplasmic Reticulum Oxidative Stress Promotes Glutathione-Dependent Oxidation of Collagen-1A1 and Promotes Lung Fibroblast Activation. Am J Respir Cell Mol Biol 71(5):589\u2013602. https:\/\/doi.org\/10.1165\/rcmb.2023-0379OC","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"5705_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12964-025-02057-7","volume":"23","author":"BH Ferreira","year":"2025","unstructured":"Ferreira BH, Silva IS, Mendes A, Leite-Pinheiro F, Paton AW, Paton JC et al (2025) Promoting ER stress in a plasmacytoid dendritic cell line drives fibroblast activation. Cell communication signaling: CCS 23(1):66. https:\/\/doi.org\/10.1186\/s12964-025-02057-7","journal-title":"Cell Communication Signaling: CCS"},{"issue":"2","key":"5705_CR47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.apsb.2022.10.017","volume":"13","author":"C Gan","year":"2023","unstructured":"Gan C, Wang J, Mart\u00ednez-Ch\u00e1vez A, Hillebrand M, de Vries N, Beukers J et al (2023) Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism. Acta Pharm Sinica B 13(2):618\u2013631. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.017","journal-title":"Acta Pharm Sinica B"},{"key":"5705_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci137845","author":"D Capece","year":"2021","unstructured":"Capece D, D\u2019Andrea D, Begalli F, Goracci L, Tornatore L, Alexander JL et al (2021) Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma. J Clin Investig. https:\/\/doi.org\/10.1172\/jci137845","journal-title":"J Clin Investig"},{"issue":"9","key":"5705_CR49","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1097\/js9.0000000000001684","volume":"110","author":"JX Lei","year":"2024","unstructured":"Lei JX, Wang R, Hu C, Lou X, Lv MY, Li C et al (2024) Deciphering tertiary lymphoid structure heterogeneity reveals prognostic signature and therapeutic potentials for colorectal cancer: a multicenter retrospective cohort study. Int J Surg (London England) 110(9):5627\u20135640. https:\/\/doi.org\/10.1097\/js9.0000000000001684","journal-title":"Int J Surg (London England)"},{"issue":"6","key":"5705_CR50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.Ccr-22-1031","volume":"29","author":"KB Kennel","year":"2023","unstructured":"Kennel KB, Bozlar M, De Valk AF, Greten FR (2023) Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res: Official J Am Association Cancer Res 29(6):1009\u20131016. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1031","journal-title":"Clin Cancer Res: Official J Am Association Cancer Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05705-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05705-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05705-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:41Z","timestamp":1792569341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05705-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5705"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05705-9","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bioinformatics data were downloaded from publicly available databases. The study involving patient data in this database was approved by the institutional ethics committee, and all patients provided informed consent.\u00a0All experimental procedures in this study were reviewed and approved by the Medical Ethics Committee of Jiangxi Cancer Hospital (Approval No. 2025ky019), which covers both animal and clinical research. Animal experiments were performed in strict accordance with the Guiding Principles in the Care and Use of Animals (China) and complied with the ARRIVE guidelines. Clinical sample experiments were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to sample collection, ensuring that they were fully informed and voluntarily agreed to the use of their samples for research purposes.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}